On March 25, the National Medical Products Administration (NMPA) and the National Health Commission (NHC) announced that, in accordance with the Drug Administration Law of the People's Republic of China, the 2025 edition of the Chinese Pharmacopoeia was reviewed and approved by the 12th Pharmacopoeia Commission Executive Committee and is now officially released.
Marketing authorization holders, pharmaceutical manufacturers, and drug registration applicants should actively prepare for the implementation of this edition of the Chinese Pharmacopoeia. They should promptly report any issues encountered during execution to the Chinese Pharmacopoeia Commission while continuously improving drug quality standards to enhance quality control.
The Chinese Pharmacopoeia is the country's official compendium of drugs and contains both traditional Chinese and Western medicines.
For details and the full catalog of the 2025 edition of the Chinese Pharmacopoeia, please refer to the announcement from the National Medical Products Administration.
If you need any assistance or have any questions, please get in touch with us via service@cirs-group.com.
Further Information
